Amylyx Pharmaceuticals Inc.

19.47+0.2100+1.09%Vol 509.46K1Y Perf -
Jul 1st, 2022 16:00 DELAYED
BID19.44 ASK20.15
Open18.85 Previous Close19.26
Pre-Market- After-Market19.47
 - -  - -%
Target Price
27.25 
Analyst Rating
Strong Buy 1.40
Potential %
39.96 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
48.18 
Earnings Rating
Market Cap1.14B 
Earnings Date
11th Aug 2022
Alpha-0.17 Standard Deviation0.44
Beta-2.31 

Today's Price Range

18.7420.35

52W Range

6.5133.41

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
4.06%
1 Month
99.28%
3 Months
51.16%
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AMLX19.470.21001.09
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.75-0.93-24.00
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.90
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume509.46K
Shares Outstanding58.53K
Shares Float28.46M
Trades Count6.57K
Dollar Volume10.01M
Avg. Volume949.47K
Avg. Weekly Volume506.04K
Avg. Monthly Volume1.55M
Avg. Quarterly Volume794.07K

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) stock closed at 19.47 per share at the end of the most recent trading day (a 1.09% change compared to the prior day closing price) with a volume of 509.46K shares and market capitalization of 1.14B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. Amylyx Pharmaceuticals Inc. CEO is Justin Klee / Joshua Cohen.

The one-year performance of Amylyx Pharmaceuticals Inc. stock is %, while year-to-date (YTD) performance is %. AMLX stock has a five-year performance of %. Its 52-week range is between 6.51 and 33.41, which gives AMLX stock a 52-week price range ratio of 48.18%

Amylyx Pharmaceuticals Inc. currently has a PE ratio of -8.50, a price-to-book (PB) ratio of 4.55, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.18%, a ROC of -48.93% and a ROE of -50.32%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Amylyx Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.90 for the next earnings report. Amylyx Pharmaceuticals Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Amylyx Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $27.25, which is +39.96% compared to the current price. The earnings rating for Amylyx Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amylyx Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amylyx Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 67.61, ATR14 : 1.82, CCI20 : 89.02, Chaikin Money Flow : -0.07, MACD : 2.27, Money Flow Index : 79.02, ROC : 20.26, RSI : 66.28, STOCH (14,3) : 84.18, STOCH RSI : 0.28, UO : 59.26, Williams %R : -15.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amylyx Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.00

Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

CEO: Justin Klee / Joshua Cohen

Telephone: +1 617 682-0917

Address: 43 Thorndike Street, Cambridge 02141, MA, US

Number of employees: 110

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

64%36%

Bearish Bullish

69%31%

TipRanks News for AMLX

Mon, 13 Jun 2022 15:55 GMT Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 03 Jun 2022 14:55 GMT Amylyx Pharmaceuticals Inc (AMLX) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 16:51 GMT Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), InflaRx (IFRX) and Aerovate Therapeutics (AVTE)

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 16:39 GMT Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX) and InflaRx (IFRX)

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 02:38 GMT Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 02:27 GMT Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy Rating from Evercore ISI

- TipRanks. All rights reserved.

News

Stocktwits